N&O Index Card
Subject/Name: Glaxo Inc.
Article(s) Referenced In:
- Glaxo gets OK to sell new drug; Zofran stops nausea during chemotherapy - Ja 8 91 1D
- Glaxo reassigns top executives - Ja 10 91 6C
- Glaxo won't join Durham downtown project - Ja 15 91 5B
- Glaxo plans to build $20 million facility in RTP - Ja 29 91 1D
- Glaxo gives $1 million to NCCU for sciences - Fe 13 91 2B
- Glaxo Inc. numbers revealing - Fe 24 91 1F
- Glaxo taps Haber for senior post - Mr 12 91 1D
- Glaxo denies reports it will cut retail prices - Mr 22 91 6C
- Glaxo gives $1 million for Duke professorship - Ap 16 91 1D
- Glaxo's darling targeted; Generic firm's suit challenges Zantac - My 12 91 1F
- Glaxo shares take off - My 25 91 10C
- Glaxo migraine drug (Imitrex) - My 26 91 1F
- Glaxo Inc. child-care centers are planned; Construction slated to be finished in year - Jn 5 91 6C
- Studies a shot in the arm for Glaxo migraine drug - Jn 9 91 2F
- Glaxo stock falls after Barron's questions potential of big drugs - Jn 18 91 1D
- Glaxo begins marketing new skin-disease drug - Jy 17 91 10C
- Glaxo says ruling helps in patent squabble with SmithKline - Jy 30 91 1D
- Glaxo opens new center for training sales force - Au 1 91 7C
- Glaxo transfers building to UNC - Au 13 91 3B
- RTP's Glaxo reports 17% surge in sales - Se 13 91 6C
- Glaxo's ulcer drug could lead shift to over-the-counter sales - Se 15 91 3F
- Glaxo retains right to develop Zantac for sale over counter - Oc 12 91 8C
- Glaxo patent tested; Canadian firm eyes ulcer drug - Oc 22 91 1D
- Glaxo gets go-ahead for migraine drug; Treatment expected to be a big seller - Oc 26 91 10C
- Glaxo, Calif. firm team up on metabolism drug - Oc 30 91 9C
- Glaxo eyes Kenly plant - No 3 91 1F
- Ulcer patient claims Glaxo ties tainted judge - No 9 91 10C
- Glaxo to buy plant Bristol-Myers closed (in Kenly) - No 13 91 9C
- Glaxo completes deal for former Bristol plant - No 21 91 5C
- Glaxo grants to help reduce infant deaths - No 22 91 5B
- Former Glaxo worker (DONNELLY) admits selling samples; Sale of ulcer drug Zantac spanned 21
- months - No 27 91 9C
- Glaxo Inc. to reorganize roles of some executives - De 20 91 6C
- 212
See a typo in our data? Let us know and we'll fix it.
Places you might find this article:
Search For This Topic
Help us correct this text for future researchers.
Type your transcription below – don't worry about formatting. Please include the line number you are correcting.
Thank you!